TC Biopharm’s shares are trending higher in pre-market trading this morning. Up almost 70% trading around $1.07 on heavy volume and more than 16,000 trades.

TC Biopharm’s shares are trending higher in pre-market trading this morning. Up almost 70% trading around $1.07 on heavy volume and more than 16,000 trades.

TC Biopharm (Holdings) PLC (“TC Biopharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, announced today announced the formation of a scientific advisory board (SAB) to advance its gamma-delta T cell therapy, OmnImmune, for the treatment of Acute Myeloid Leukemia (AML).

Company recently announced an offering.

Commercial satellite company lands Government contract and sends shares soaring. Read about this 100% mover with record volume and 346,000 trades.

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist